CVS Health Corp. Revenue, History, and Strategy

CVS Health Corp.: Key Facts

• CVS Health Corp. Was founded in 1963.
• Founded by Stanley Goldstein, Sidney Goldstein, Ralph Hoagland.
• Headquarters: Woonsocket, Rhode Island.
• Country: United States.
• CEO: David Joyner.
• Approximately 300K employees worldwide.
• Market capitalization: $65.0B.
• Annual revenue: $372.0B (FY2024).
• Net income: $4.6B.
• Industry: Healthcare / Pharmacy Retail.
• Listed on a public stock exchange.
• CVS did not begin as a pharmacy — the original 1963 Consumer Value Store sold health and beauty products without dispensing prescriptions, only adding pharmacy services in the 1970s
• CVS Caremark was formed through a contentious 2007 merger that involved a competing bid from Express Scripts, the same company CVS was seeking to rival
• The company forfeited approximately $2 billion in annual tobacco revenue in 2014 when it voluntarily removed all tobacco products from its more than 7,600 stores at the time
• Aetna was founded in 1853 — more than 110 years before CVS was founded — making it one of America's oldest insurance companies when CVS acquired it in 2018
• Oak Street Health, acquired by CVS in 2023 for $10.6 billion, operates a value-based care model specifically designed for Medicare patients in urban and underserved communities
• CVS's total revenues of approximately $372 billion in fiscal year 2024 exceed the GDP of countries including Denmark, Singapore, and New Zealand
• Rite Aid's 2023 bankruptcy, which resulted in hundreds of store closures, benefited CVS through prescription transfers from closing Rite Aid locations
• CVS employed approximately 300,000 people in 2024, making it one of the thirty largest private employers in the United States by headcount
• CVS voluntarily removed $2 billion in annual tobacco sales from its stores in 2014 — the largest deliberate self-inflicted revenue cut in American retail history — as a signal of its transformation into a health company
• The 2018 Aetna acquisition for $69 billion was the largest healthcare deal in U.S. History and grafted America's oldest health insurer onto what had been primarily a pharmacy chain
• More than 90 percent of Americans live within ten miles of a CVS Pharmacy, a geographic density that took six decades of real estate investment to build
• CVS processes more than 2 billion prescription claims per year through Caremark, making it the single largest pharmacy benefit manager in the United States
• A 2024 Medicare Advantage underwriting crisis severe enough to end CEO Karen Lynch's tenure highlights the risks of CVS's vertical integration bet

CVS Health Corp.: CVS Health Corp.: CVS Health Corp. Company Timeline

What Is the History of CVS Health Corp.?

The story of CVS Health begins not in a hospital or a pharmaceutical laboratory but in a shopping mall — specifically, in the growing consumer shopping culture of early 1960s New England, where three entrepreneurs saw an opportunity to bring a new kind of value-oriented retail concept to health and beauty shoppers.

In 1963, Stanley Goldstein, Sidney Goldstein, and Ralph Hoagland opened the first Consumer Value Store in Lowell, Massachusetts. The name itself tells you what the founders were selling: not healthcare, not prescriptions, not insurance, but value. The store was part of the Melville Corporation, a Massachusetts-based conglomerate with retail holdings that ranged from shoe stores to apparel chains. Consumer Value Store — CVS — was designed to compete in the health, beauty, and personal care product space, differentiating itself from drugstores through a focus on product value and selection rather than the full-service pharmacy model that anchored traditional apothecaries and chain drugstores of the era.

The early CVS stores did not initially dispense prescriptions at all. This is a fact that tends to surprise people given how central pharmacy has been to CVS's identity for the past four decades. The founding concept was closer to what we would today call a health and beauty retailer — think early Target health and beauty aisles rather than Walgreens. It was not until the 1970s that CVS expanded into prescription pharmacy services, adding pharmacists and dispensing counters as the company recognized that full-service pharmacy was essential to competing for the health-oriented shopper who was increasingly becoming the core CVS customer.

Growth through the late 1960s and 1970s was organic, driven by store openings primarily in the northeastern United States. New England and the Mid-Atlantic states became the company's stronghold. CVS developed a reputation for competitive pricing on over-the-counter health products and built the store format — accessible, well-lit, organized around health and personal care categories — that would remain largely recognizable for the next half-century.

The transformative decade for CVS's physical growth was the 1980s and 1990s, when the company pursued an aggressive acquisition strategy that expanded its geographic reach from a regional New England chain to a national drugstore powerhouse. The 1990 acquisition of the Peoples Drug chain, which operated approximately 490 stores primarily in the Mid-Atlantic states, represented a defining expansion moment that doubled CVS's footprint and gave it a competitive presence in major markets including Washington, D.C., Baltimore, and Pittsburgh. In 1996, CVS separated from its Melville Corporation parent, becoming an independent publicly traded company listed on the New York Stock Exchange under the ticker CVS.

The 1997 acquisition of Revco Drug Stores — a Midwestern chain with approximately 2,500 locations — was the largest drugstore acquisition in American history at the time and pushed CVS firmly into the national tier of pharmacy retail alongside Walgreens and Rite Aid. Revco gave CVS deep penetration into Ohio, Michigan, Indiana, and neighboring states, transforming a northeastern regional chain into a coast-to-coast competitor. The 1998 acquisition of Arbor Drugs in Michigan and the 1999 acquisition of Soma.com's online pharmacy operations continued the growth cadence.

By the turn of the millennium, CVS had grown into one of America's largest drugstore chains by store count and pharmacy prescription volume. But the growth trajectory that had defined the company's first four decades — open stores, acquire chains, repeat — was approaching its natural limits. The national pharmacy retail market was maturing, reimbursement rates were declining, and the future of prescription drug distribution appeared increasingly likely to flow through pharmacy benefit managers who were capturing control of the pharmacy economics that had underpinned CVS's business model. The company's leadership recognized that staying purely in retail pharmacy meant accepting a secular decline in margins with limited strategic recourse.

The answer, though it would take years to fully reveal itself, was vertical integration — moving upstream in the healthcare value chain to capture not just the dispensing margin but the broader economics of pharmaceutical benefit management, and ultimately, the even broader economics of health insurance and primary care. That strategic vision would define everything that followed.

CVS Health Corp. Stands at a pivotal inflection point in its corporate evolution, having spent the better part of a decade and more than $100 billion in acquisition capital assembling what it describes as a uniquely integrated American healthcare company. The Woonsocket, Rhode Island-based corporation operates in a sector that accounts for nearly one-fifth of U.S. Gross domestic product, serving patients across the full arc of healthcare engagement from the moment they need a common cold remedy at a CVS Pharmacy storefront through the complexity of managing a chronic condition through an Aetna insurance plan, filling a specialty biologic prescription through Caremark, and receiving primary care from an Oak Street physician.

The scale of CVS's operations is genuinely staggering. In a single year, its pharmacy operations dispense hundreds of millions of prescriptions, its insurance operations pay out billions in medical claims, and its MinuteClinic and Oak Street platforms handle millions of clinical encounters. The company's annual revenue exceeds the gross domestic product of many mid-sized countries. Yet size alone has never guaranteed profitability or competitive durability in healthcare — a sector where regulatory complexity, clinical quality requirements, and government pricing power create dynamics that resist the straightforward application of retail or financial services business logic.

CVS Health's current chapter is one of recalibration — a recognition that integration at this scale requires not just capital but sustained operational excellence across wildly different business functions, and that the financial markets will not indefinitely subsidize a strategy whose returns remain unclear.

Early Challenges

The path from Consumer Value Store to CVS Health was not a smooth upward trajectory. The company's early decades were punctuated by strategic misfires, competitive setbacks, and moments when the business model itself appeared fundamentally challenged — moments that required hard choices about what kind of company CVS wanted to be.

In the late 1970s and early 1980s, as CVS was expanding its pharmacy services and growing its New England footprint, the company faced the challenge common to all drugstore chains of the era: defining a competitive identity in a market where Walgreens to the west, Rite Aid to the south, and independent pharmacies in every local market were fighting for the same prescription dispensing customer. CVS's response was to double down on its value-oriented positioning in front-of-store merchandise while building pharmacy expertise — a dual positioning that worked in theory but required constant execution to prevent the store from feeling like neither a true pharmacy nor a true discount retailer.

The Melville Corporation parentage, which provided capital and corporate infrastructure during CVS's formative years, also constrained the chain's identity. As part of a conglomerate that owned Footwear, apparel, and furniture chains, CVS was never the primary strategic priority. Resources flowed according to Melville's portfolio logic, not necessarily according to CVS's greatest growth opportunities. When CVS finally separated from Melville in 1996 to become an independent NYSE-listed company, the independence created both freedom and exposure — freedom to pursue its own capital allocation, exposure to the full scrutiny of public markets without a parent's balance sheet as backstop.

The late 1990s brought a different kind of challenge: the dot-com era's promise that the internet would disintermediate pharmacy retail. CVS, like virtually every established retailer of the period, grappled with how to respond to the emergence of online pharmacy startups like PlanetRx and drugstore.com that promised to deliver prescriptions to consumers' homes at competitive prices. CVS launched its own online pharmacy, Soma.com (acquired in 1999), and tried to establish a credible digital presence, but the fundamental economics of e-commerce pharmacy were challenging — margins were thin, delivery logistics were complex, and consumers proved more attached to the walk-in pharmacy habit than Silicon Valley optimists had predicted. Most dot-com pharmacy competitors went bankrupt in the 2000-2001 bust, vindicating the brick-and-mortar model but also deferring rather than resolving the long-term question of digital pharmacy disruption.

The 2000s presented a more structural challenge: the explosive growth of pharmacy benefit managers who were increasingly inserting themselves between drugstore chains and the insurance plans that paid for the majority of prescription revenues. As PBMs — led by Caremark, Medco, and Express Scripts — gained market power, they used that power to negotiate lower reimbursement rates from retail pharmacies, direct patients toward mail-order dispensing, and effectively commoditize the prescription dispensing service that CVS had built its business around. By the mid-2000s, it was increasingly apparent that a retail pharmacy that didn't also control a significant PBM business was structurally disadvantaged — dependent on PBM terms it couldn't fully control.

CVS's strategic response to this threat was the most important decision in the company's history: rather than fight the PBMs as an adversary, acquire one. The 2007 merger with Caremark Rx, completed in March 2007 after a contentious bidding war with Express Scripts, was transformative. The combined company, renamed CVS Caremark Corporation, immediately became one of the largest healthcare companies in the United States by revenue and gave CVS the PBM capabilities it had lacked. But the merger was not smooth. It involved a difficult proxy contest, shareholder opposition, and competing bids that complicated the negotiating process. After the deal closed, integrating two fundamentally different business cultures — a retail drugstore chain and a healthcare services IT and administrative company — proved operationally complex. Early years of the combined entity were marked by customer retention challenges in the Caremark business as some clients expressed concern about the conflict of interest inherent in a PBM owned by a retail pharmacy chain. Express Scripts and other competitors actively used the perceived conflict to win Caremark business away.

The integration difficulties taught CVS a lesson that would prove insufficiently heeded in subsequent years: buying a large, complex company does not instantly produce operational operational efficiencies or resolve structural conflicts. The hard work comes after the deal closes, in the day-to-day execution of running businesses that may have historically different cultures, systems, and strategic orientations under a unified management structure. This lesson would need to be relearned, at far higher cost, when Aetna was acquired in 2018.

Retail Pharmacy to Integrated Pharmacy Services

The merger with Caremark Rx represented CVS's first major strategic pivot — a shift from pure retail pharmacy operator to integrated pharmacy services company encompassing both dispensing and pharmacy benefit management. This pivot was driven by the recognition that PBM consolidation was commoditizing retail pharmacy reimbursement and that CVS needed to capture a position in the PBM layer of the pharmaceutical supply chain to preserve its long-term competitive position.

Drugstore Chain to Healthcare Company

The removal of tobacco products from all CVS locations and the simultaneous rebranding from CVS Caremark to CVS Health marked a philosophical and operational pivot from retail pharmacy to healthcare company identity. This pivot involved forgoing an estimated $2 billion in annual tobacco revenues to establish credibility as a genuine healthcare partner rather than a convenience retailer that dispensed prescriptions. The rebranding signaled to healthcare system partners, insurers, employers, and regulators that CVS aspired to a different role in the healthcare system.

Pharmacy and PBM Company to Integrated Health Insurer

The Aetna acquisition was the most dramatic strategic pivot in CVS's history — a $69 billion bet that the company could become an integrated health insurer, PBM, and retail pharmacy simultaneously. This pivot introduced CVS to the underwriting risk dynamics of health insurance, the regulatory complexity of operating a major insurance company, and the challenge of coordinating care across insurance, pharmacy, and clinical functions at national scale.

Insurance and PBM to Primary Care Provider

The Oak Street Health acquisition added primary care physician services to CVS's portfolio, completing the company's transformation into a vertically integrated healthcare company spanning clinical care, insurance, PBM, and pharmacy. This pivot positioned CVS as a direct provider of medical services — employing or contracting with primary care physicians who manage patient health on a capitated basis — a role that retail pharmacy chains had never previously occupied at scale in American healthcare.

CVS Health Corp.: CVS Health Corp.: Expert Analysis

CVS Health Corp.: CVS Health Corp.: Founders

How Does CVS Health Corp. Make Money?

CVS Health operates one of the most complex and multi-layered business models in American corporate history — a structure that interweaves retail pharmacy economics, insurance underwriting, pharmaceutical distribution intermediation, and primary care delivery into four distinct but increasingly interdependent segments. Understanding how CVS makes money requires understanding each of these segments individually and then grasping the strategic logic behind connecting them.

The Health Care Benefits segment, anchored by the Aetna brand, is CVS Health's insurance operations. This segment provides medical, pharmacy, dental, and behavioral health benefits to approximately 26 million medical members through commercial employer plans, individual and family plans sold on the Affordable Care Act exchanges, Medicare Advantage plans, and Medicaid managed care contracts. Revenue in this segment flows primarily from insurance premiums — the monthly payments collected from employers, government programs, and individuals in exchange for coverage. In fiscal year 2024, Health Care Benefits generated approximately $120 billion in premium revenues. The economic engine of insurance is the medical loss ratio (MLR) — the share of premium revenue paid out in claims. When MLR is low, the segment generates meaningful underwriting profit. When it rises — as it did sharply in 2024, reaching levels above 90 percent in some quarters due to elevated utilization in Medicare Advantage — the segment produces underwriting losses that can rapidly erase the value of the premium base. This dynamic drove much of CVS Health's profitability crisis in 2024.

The Pharmacy & Consumer Wellness segment is the company's retail and mail-order pharmacy operation, encompassing the branded CVS Pharmacy storefronts, the MinuteClinic walk-in clinic network inside CVS locations, and the growing HealthHUB store format. This segment generated approximately $95 billion in revenues in fiscal year 2024. Revenue here comes from two primary sources: pharmacy dispensing (filling prescriptions in exchange for reimbursement from insurance plans and government programs, plus patient copays) and front-end retail sales (over-the-counter medications, personal care products, seasonal merchandise, and convenience goods). Pharmacy dispensing accounts for roughly 80 percent of this segment's revenues. The economics are challenging: retail pharmacy reimbursement rates have been squeezed for years by PBMs — ironically including CVS's own Caremark — which negotiate reimbursement on behalf of payers. Front-end retail has faced structural pressure from mass retailers and e-commerce. The MinuteClinic network, with approximately 1,100 locations, provides primary care, urgent care, and chronic disease management services, primarily serving patients who use CVS pharmacies. These clinics are important strategically for deepening patient relationships but remain a relatively small financial contributor compared to dispensing revenues.

The Health Services segment, primarily anchored by CVS Caremark, is the company's pharmacy benefit management (PBM) operation and one of the largest and most financially consequential PBM businesses in the world. Caremark manages pharmacy benefits for health plan sponsors — employers, unions, government entities, and health insurers — processing more than 2 billion prescription claims annually. The PBM business model is layered and opaque. Caremark earns revenue through administrative fees charged to plan sponsors, spread pricing (the difference between what it charges a plan sponsor for a drug and what it pays the dispensing pharmacy), and rebates negotiated with pharmaceutical manufacturers that may or may not be fully passed through to plan sponsors depending on contract terms. In fiscal year 2024, the Health Services segment generated approximately $170 billion in revenues, though much of this figure represents drug costs flowing through Caremark's books rather than pure economic value created. Adjusted operating income is a more meaningful measure of economic contribution from this segment. Caremark also operates specialty pharmacy services for high-cost complex medications, a segment of rapidly growing importance as biologic and gene therapy drugs become more prevalent.

The fourth pillar is the company's expanding primary care footprint through Oak Street Health, acquired in May 2023 for approximately $10.6 billion. Oak Street operates a value-based primary care model specifically designed for Medicare-eligible patients, predominantly in urban markets and underserved communities. Under value-based care arrangements, Oak Street receives a fixed per-patient capitated payment from Medicare Advantage plans to provide comprehensive primary care services. Its economics depend on managing total cost of care below the capitated payment — essentially running the clinical operation efficiently enough to generate a margin on the capitation. Oak Street had approximately 188 centers at time of acquisition and has continued expanding under CVS ownership. Financially, the segment is early-stage relative to CVS's other businesses, still investing heavily in center openings, but strategically represents a crucial link in CVS's integrated care thesis: if CVS can manage a patient's insurance coverage through Aetna, fill their prescriptions through Caremark and CVS Pharmacy, and provide their primary care through Oak Street, the company captures healthcare dollar from multiple angles while theoretically improving care coordination and reducing total medical costs.

Cross-segment economics represent the final layer of the CVS business model — and the most controversial. The company's integrated structure means that Aetna plans can direct members to CVS pharmacies, Caremark can serve as the preferred PBM for Aetna, and Oak Street patients can be seamlessly referred into the broader CVS network. Critics, including regulators and competing health systems, argue that these vertical relationships create conflicts of interest, particularly in the PBM context, where Caremark's decisions about which drugs to cover and reimburse at what rates affect both payer clients and CVS's own retail pharmacy. Defenders argue that integration genuinely reduces friction, lowers costs, and improves health outcomes for patients who engage with the full CVS ecosystem. The empirical truth lies somewhere between these poles and is difficult to disentangle from the company's reported financial results. What is certain is that the model requires immense capital, operational complexity spanning multiple regulated industries, and a management team capable of simultaneously running a retail chain, an insurance company, a PBM, and a clinical care network — a challenge that has proved more demanding than investors initially anticipated when the Aetna deal closed in 2018.

Revenue Streams

• Health Services (Caremark PBM) (46): The Health Services segment, primarily CVS Caremark, is the largest revenue contributor, processing more than 2 billion prescription claims annually for employer, government, and health plan clients. Revenue flows from administrative fees, spread pricing, specialty pharmacy dispensing, and rebate management. This segment also includes Caremark's mail-order pharmacy operations and the SilverScript Medicare Part D plan.
• Health Care Benefits (Aetna Insurance) (22): The Health Care Benefits segment represents Aetna's insurance operations, generating revenue primarily through premium collections from approximately 26 million medical members enrolled in commercial, Medicare Advantage, Medicare supplement, and Medicaid managed care plans. Profitability depends on maintaining medical loss ratios at levels that preserve underwriting margin after claims payments.
• Pharmacy and Consumer Wellness (Retail Stores) (25): The Pharmacy and Consumer Wellness segment generates revenue through prescription dispensing reimbursements at CVS Pharmacy's 9,000-plus retail locations and front-end retail sales of over-the-counter products, personal care items, and convenience merchandise. MinuteClinic clinical encounter fees are also captured in this segment.
• Oak Street Health and Other Health Services (5): This segment captures revenues from Oak Street Health's value-based primary care operations, where income flows from capitated Medicare Advantage payments per enrolled patient. Additional revenues include other health services operations not captured in the primary three segments, including digital health services and certain clinical management programs.
• Corporate and Other (2): Corporate and other revenues capture intercompany adjustments, investment income, and miscellaneous revenues not allocated to primary business segments. This category is primarily relevant as an accounting reconciliation item rather than a material independent revenue generator.

What Products and Services Does CVS Health Corp. Offer?

What Is CVS Health Corp.'s Competitive Advantage?

CVS Health's most durable competitive advantages are structural in nature — they derive from assets that took decades and tens of billions of dollars to assemble and that cannot be replicated quickly by any competitor.

The company's physical pharmacy network, encompassing more than 9,000 retail locations, represents an unmatched point-of-care touchpoint density. The frequently cited statistic — that more than 90 percent of the U.S. Population lives within ten miles of a CVS Pharmacy — is not merely a marketing talking point. It reflects a genuine geographic coverage advantage that gives CVS the ability to serve as a point of prescription pickup, vaccination administration, acute care visit, and chronic disease monitoring at a scale that no competitor can match without decades of real estate investment. Amazon can deliver medications, but it cannot administer a flu shot at 8 PM on a Tuesday in rural Ohio.

Caremark's PBM scale is equally formidable. Processing more than 2 billion prescription claims annually, Caremark has the negotiating leverage to extract meaningful manufacturer rebates, the data assets to identify cost management opportunities, and the employer relationships that represent sticky, multi-year contracts. While PBM regulatory risk is real, the sheer operational complexity of transitioning a large employer's pharmacy benefits to a new administrator creates inherent switching costs that benefit incumbents like Caremark.

Vertical integration across insurance, PBM, retail pharmacy, and primary care creates data and coordination advantages that point-solution competitors cannot match. When CVS can analyze a patient's prescription adherence data, insurance claims history, and clinical visit records simultaneously, it has a far richer picture of that patient's health status than any single-function competitor can assemble. The ability to close care gaps — identifying patients who are not filling critical prescriptions or who have missed preventive screenings — is both clinically valuable and economically significant under value-based care models.

Brand recognition and consumer trust, built over sixty years of retail pharmacy presence in American communities, provide a softer but meaningful advantage in consumer-facing healthcare. Americans are accustomed to walking into CVS for healthcare needs across a broad spectrum, from picking up antibiotics to getting a COVID booster, and that habitual engagement is a valuable asset in a sector where consumer trust is a prerequisite for clinical relationship-building.

Who Are CVS Health Corp.'s Main Competitors?

The competitive landscape for CVS Health in 2025 is unlike anything the company faced during its first four decades as a retail pharmacy chain. Then, competition came primarily from Walgreens, Rite Aid, and independent pharmacies — traditional brick-and-mortar rivals competing on store count, location quality, and prescription pricing. Today, CVS competes simultaneously across four distinct competitive arenas: retail pharmacy, pharmacy benefit management, health insurance, and primary care delivery. Each of these arenas has its own competitive dynamics, and the roster of rivals in each is different.

In retail pharmacy, Walgreens Boots Alliance remains the most direct competitor, with approximately 8,600 U.S. Locations as of early 2025. Walgreens has faced its own profound financial difficulties — the company has closed hundreds of stores, its stock reached multi-decade lows, and it has been exploring strategic alternatives including potential privatization. Rite Aid filed for bankruptcy in 2023, closing hundreds of stores and emerging as a dramatically reduced competitor. The retreat of Rite Aid has created an opportunity for CVS and Walgreens to absorb prescription transfers from closing locations, which has partially mitigated the reimbursement rate pressure both companies face.

Beyond traditional pharmacy rivals, Amazon Pharmacy represents a structurally different kind of threat. Since acquiring PillPack in 2018 for approximately $753 million, Amazon has built a digital pharmacy offering that combines competitive pricing on generics, home delivery, and seamless integration with the Amazon Prime ecosystem. Amazon's 2023 expansion of its One Medical primary care membership service — available to Prime members — adds a clinical layer that mirrors CVS's own integrated ambitions from a purely digital and in-home direction. Amazon's competitive threat is particularly acute among younger, urban, digitally native consumers who are increasingly comfortable managing healthcare needs through their smartphones and who have less attachment to the physical pharmacy habit that anchors CVS's customer base.

In the pharmacy benefit management arena, CVS Caremark competes primarily with Express Scripts (owned by Cigna's Evernorth health services division) and OptumRx (owned by UnitedHealth Group). These three PBMs collectively manage pharmacy benefits for the vast majority of Americans with commercial insurance. The competitive dynamics are driven by employer contracting cycles, rebate guarantees, administrative capabilities, and specialty pharmacy services. Regulatory scrutiny represents a shared threat to all three, though the outcome of potential PBM reform legislation would reshape the competitive landscape in ways that are difficult to predict with precision.

In health insurance, Aetna competes with UnitedHealthcare, Anthem (now Elevance Health), Cigna, Humana, and a host of regional Blue Cross Blue Shield plans. UnitedHealth Group is the dominant force, with revenues exceeding $370 billion in 2024 and a deeply integrated model through its Optum subsidiary that in many respects resembles and competes directly with CVS's integrated ambitions. The comparison between CVS/Aetna and UnitedHealth/Optum is instructive: UnitedHealth began building its integrated model much earlier and has executed with notably greater consistency. Elevance Health and Humana are formidable in commercial and Medicare markets respectively. In Medicare Advantage specifically — the segment that caused CVS's 2024 financial crisis — competition is intense, with CMS reimbursement rates determining industry profitability in ways that no single insurer can fully control.

In primary care, the competitive field has become remarkably crowded. Federally Qualified Health Centers, hospital systems, independent physician groups, Walmart Health (before its closure in 2024), One Medical/Amazon, and Village Medical (owned by Walgreens) have all competed for the primary care patient relationship. The closure of Walmart Health in 2024, following the company's assessment that the economics of retail-based primary care were unworkable, was simultaneously a cautionary data point and a competitive development that may benefit CVS's Oak Street Health as Medicare-eligible patients in markets Walmart served now seek alternatives.

The meta-competitive question facing CVS is whether vertical integration — its core strategic bet — actually creates sustainable competitive advantage or merely operational complexity. UnitedHealth Group's success suggests that integration can work, but UnitedHealth has had decades more time to refine its model. CVS assembled its integrated stack through three large acquisitions in roughly seven years, each at peak valuations, and has struggled to extract the expected operational efficiencies at the pace investors anticipated. The competitive challenge, in this sense, is not merely external — it is internal, a question of whether CVS can manage a portfolio of businesses that span retail, insurance, technology, and clinical care with sufficient operational discipline to generate the returns that justify the capital invested.

How Has CVS Health Corp.'s Revenue Grown Over Time?

CVS Health's financial profile in fiscal year 2024 reflects the tension between extraordinary scale and profitability under pressure. Total revenues reached approximately $372 billion, a figure that places CVS among the top five largest companies in the United States by this measure — yet much of this revenue represents pharmaceutical product costs flowing through the PBM and insurance segments rather than margin-generating operating income. The company's adjusted operating income, a measure that strips out depreciation, amortization of acquired intangibles, and restructuring charges, provides a cleaner picture of economic performance, and that figure declined meaningfully in 2024 relative to prior years, driven primarily by Aetna's elevated medical cost ratios in its Medicare Advantage business.

The Health Care Benefits segment — Aetna — reported a medical loss ratio that breached 90 percent in multiple quarters of 2024, a level that signals minimal or negative underwriting margin. This drove CVS to reduce its full-year earnings guidance multiple times during 2024 and ultimately contributed to net losses that surprised even cautious analysts. The company's net income for fiscal year 2024 was approximately $4.6 billion on a GAAP basis, though this figure includes significant charges. Long-term debt stood at approximately $73 billion, a legacy of the Aetna and other acquisitions, which creates meaningful interest expense that further pressures earnings.

The Health Services segment (Caremark) remains the most profitable segment on an adjusted basis, contributing the majority of CVS's adjusted operating income. The Pharmacy & Consumer Wellness segment generates substantial revenue but thin margins reflective of retail pharmacy economics. CVS generated approximately $9 billion in operating cash flow in 2024, which it has used to service debt, fund capital expenditures including Oak Street center openings, and maintain its dividend — currently approximately $2.66 per share annually.

Revenue History Source: SEC filing

What Companies Has CVS Health Corp. Acquired?

CVS Health Corp.: CVS Health Corp.: Controversies & Legal Issues

Who Leads CVS Health Corp.?

How Is CVS Health Corp. Growing?

CVS Health's growth strategy under CEO David Joyner centers on three interrelated priorities that represent a course correction from the acquisition-led expansion of the Lynch era toward more disciplined organic growth and operational integration.

The first priority is deepening the integration of existing assets. For years, CVS assembled pieces — Caremark, Aetna, MinuteClinic, Oak Street — but cross-segment coordination remained incomplete. Joyner has emphasized building care management programs that connect Aetna members with Oak Street primary care, CVS pharmacists, and Caremark specialty pharmacy in coordinated pathways. The goal is to demonstrate, with concrete clinical and financial outcomes data, that integrated care actually reduces total medical costs — the foundational premise that justified the Aetna acquisition price in 2018.

The second priority is accelerating Oak Street Health's expansion in a capital-efficient manner. Rather than opening new centers at maximum speed regardless of per-center economics, CVS is targeting markets where Medicare Advantage penetration is high, where Oak Street's value-based care model can capture the greatest risk adjustment upside, and where real estate and clinical staffing costs support attractive unit economics. Management has guided toward continued center openings while improving new center maturation timelines.

The third priority is expanding digital health and pharmacy capabilities to compete with Amazon and other digital-first entrants. This includes investment in CVS's mobile app and digital prescription management, expansion of same-day and next-day delivery options, and development of digital chronic disease management programs that extend the clinical relationship beyond the physical store visit. These investments are growth-oriented but also defensive, aimed at retaining customers who might otherwise migrate to pure-play digital pharmacy alternatives.

CVS Health's trajectory over the next three to five years will be shaped by its success or failure in resolving three defining challenges: stabilizing Aetna's Medicare Advantage underwriting, managing pharmacy reimbursement economics through a period of structural compression, and demonstrating that Oak Street Health can scale to sufficient size to contribute meaningfully to enterprise profitability rather than consuming capital.

Under CEO David Joyner, appointed in October 2024, CVS has signaled a renewed focus on operational execution over headline-grabbing acquisitions. The company has announced plans to reduce its Medicare Advantage membership — accepting lower enrollment in exchange for more appropriately priced plans — a strategy that trades near-term revenue scale for better underwriting economics. This is the correct strategic choice if managed well, but it requires navigating the transition without triggering a spiral of adverse selection that further concentrates high-cost patients in remaining enrollment.

Oak Street Health's expansion represents a long-term growth vector with genuine strategic logic. Value-based primary care for Medicare patients is both clinically effective — multiple studies demonstrate lower total cost of care and better patient outcomes — and financially attractive if scaled efficiently. Oak Street's model of serving Medicare Advantage populations, including Aetna members, creates a natural alignment between clinical and financial incentives. If CVS can grow Oak Street to 300-plus centers while maintaining its quality metrics and managing per-center economics, this business could become a meaningful earnings contributor by 2027-2028.

Pharmacy services will continue evolving toward specialty medication management, biosimilar adoption, and digital prescription management, all of which create opportunities for Caremark and CVS Pharmacy to capture margin in categories where reimbursement dynamics are more favorable than in traditional generic dispensing.

What Are the Biggest Risks Facing CVS Health Corp.?

CVS Health faces a confluence of challenges in 2025 that collectively represent the most serious test of its integrated healthcare strategy since the company began assembling it. These pressures span financial, operational, regulatory, and competitive dimensions, and none of them is easily resolved through a single strategic adjustment.

The most immediate and financially damaging challenge is the deterioration of Aetna's Medicare Advantage underwriting results. In 2024, elevated medical utilization — patients using more healthcare services than actuarial models had predicted — drove CVS Health's Health Care Benefits segment into significant underwriting losses. The company took multi-billion-dollar charges related to Aetna and ultimately reported adjusted operating income that fell far short of analyst expectations. Medicare Advantage plans, which had been a growth engine for the health insurance industry for years, encountered a reckoning as pent-up post-pandemic demand, higher acuity patient populations, and inadequate premium adjustments from the Centers for Medicare & Medicaid Services (CMS) compressed margins industry-wide. For CVS specifically, the magnitude of the shortfall was severe enough to trigger the leadership change that ended Karen Lynch's tenure as CEO in October 2024.

Pharmacy reimbursement compression is a structural, secular challenge rather than a cyclical one. For years, government programs and commercial payers — often through PBMs — have progressively reduced the reimbursement rates paid to retail pharmacies for dispensing both generic and branded medications. The result is that the margin earned per prescription filled has declined steadily, making it harder for retail pharmacy operations to generate adequate returns on the physical infrastructure of store leases, pharmacist labor, and technology. CVS has responded by closing hundreds of stores — announcing the closure of approximately 900 locations between 2022 and 2024 — but store closures carry their own costs and customer disruption.

Regulatory and legislative pressure on PBMs has intensified dramatically. Congress has held multiple hearings examining PBM practices, and several states have passed laws restricting spread pricing, requiring rebate pass-through, or mandating greater PBM transparency. Federal legislation targeting PBMs has been proposed in both chambers. Caremark, as one of the three dominant PBMs alongside Express Scripts and OptumRx, sits directly in the crosshairs of this scrutiny. Any significant regulatory change to PBM economics could materially alter the revenue and margin profile of CVS's largest segment by revenue.

Competitive pressure from Amazon, which acquired PillPack in 2018 and launched Amazon Pharmacy, represents a long-term disintermediation threat. Amazon's entry into primary care through its One Medical acquisition adds a further dimension. While Amazon has not yet captured meaningful prescription market share, its combination of distribution capability, customer data, and price-competitive positioning could erode CVS's consumer-facing pharmacy volumes over time, particularly among younger and digitally native patient populations.

CVS Health Corp.: CVS Health Corp.: Quick Reference Q&A

CVS Health Corp.: CVS Health Corp.: Frequently Asked Questions: CVS Health Corp.

CVS Health Corp.: CVS Health Corp.: Sources & References

• CVS Health Corporation 2024 Annual Report on Form 10-K [sec_filing]
• CVS Health Investor Relations — Earnings Releases and Presentations [investor_relations]
• CVS Health Q4 2024 Earnings Call Transcript [earnings_call]
• CVS Health Corporate Website — Company Overview [corporate_website]
• Centers for Medicare and Medicaid Services — Medicare Advantage Data [regulatory_filing]